PHARMING

PHARMING CONFIRMS COMPLETION OF REDEMPTION OF THIRD TRANCHE AND THE REDEMPTION OF FOURTH TRANCHE OF CONVERTIBLE BOND

Leiden, The Netherlands, May 21, 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it completed the redemption of the third tranche and redeemed the fourth tranche of its €16.35 million convertible bond.

A total of 7,482,994 shares were issued to the bondholders to serve the balance between the 26,605,121 shares that were issued on 16 April, as pre-installment for the May 20, 2013 redemption and interest payment, and the total number of shares due to complete the redemption of the third tranche under the terms and conditions of the bond.

In addition 32,787,213 shares were issued to the bondholders, serving as a pre-installment for the June 21, 2013 redemption of the fourth tranche and interest payment, under the terms and conditions of the bond.

About the January 2013 Convertible Bonds

As announced in our press release on January 16, 2013, and following the approval of the increase of the Company's authorized share capital during the extraordinary general meeting of shareholders, which was held on February 28, 2013, Pharming will redeem the bond on a month by month basis in seven equal tranches, of which four have now been redeemed, such that redemption of the bond will be completed on October 01, 2013. Remaining redemption dates after 21 June are; 25 July, 28 August and 01 October.
As of today, the number of outstanding shares has increased from 168,909,635 to 209,179,842.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST is partnered with Santarus Inc (NASDAQ: SNTS) in North America where a BLA for RUCONEST was submitted to the FDA in April 2013. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that, with the EU approval of Pharming's rhC1 inhibitor, has proven capable of producing industrial volumes of high quality recombinant human protein in a significantly more economical way through low upfront capital investment and manufacturing costs, compared to current cell based technologies. Pharming now plans to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 71 524 7400

FTI Consulting
Julia Phillips/ John Dineen, T: +44 (0)207 269 7193

###